BrainMARC Ltd.

BrainMARC operates at the intersection of digital health, cognitive remediation, health diagnostics, and neurotechnology. Its stated differentiation is the BEI technology, which the company presents as a neuro-marker-based approach for measuring or supporting engagement during cognitive-remediation treatment. The platform’s reported clinical validation across the United States, Canada, the European Union, and Israel gives it a healthcare-oriented profile rather than that of a general wellness or consumer brain-training application. The company is private, has a disclosed team size of fewer than ten employees, and has raised $81,868 in disclosed funding, including a 2019 grant. Those indicators suggest an early-stage or tightly focused operation. Its potential competitive advantage rests on combining software delivery with BEI-based measurement and clinical evidence, but the scale, commercialization status, and market adoption of that approach remain unclear.

BrainMARC’s trajectory shows an early transition from founding in 2013 to outside financing and clinical development. The company completed a venture round on Mar 10, 2015 with Alon Medtech Ventures as lead investor, then received an $81,868 EISMEA grant announced on Jan 1, 2019. The funding history indicates continued support for research or product development, but the disclosed venture-round amount is unavailable, preventing a complete view of capital intensity. BrainMARC describes its BEI-enabled platform as validated through hundreds of patient cases across four geographic markets, suggesting that clinical testing and evidence generation have been important development milestones. Current employment data lists fewer than ten employees and identifies two current positions, including co-founder Goded Shahaf and VP Research and Clinical Operations Revital Sharivkin. There are no documented product launches, expansion events, hiring announcements, or later financing rounds. Accordingly, the available evidence supports a research-led, early-stage trajectory through 2019, followed by limited visibility into commercialization, workforce growth, or product scaling through Sep 30, 2026.